worldwide offices | contact | site map | large text versionregular text version

Novartis Pharmaceuticals Corporation - A site intended for US audiences

 

 

 

Newsroom

Press Releases ›

15-Apr-2008
FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment

15-Apr-2008
Patients with early Parkinson's disease show better symptom control and improvements in daily activities with Stalevo than carbidopa/levodopa

11-Apr-2008
Study shows once-yearly Reclast better than risedronate at increasing bone mass in patients with osteoporosis caused by glucocorticoids

31-Mar-2008
Novartis and FDA complete Two-year Cooperative Research and Development Agreement (CRADA) To Define and Test a Process for Qualifying Preclinical Safety Biomarkers

31-Mar-2008
Lotrel, a single-pill combination for treating high blood pressure, reduced cardiovascular events by 20% in high-risk patients


The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on Novartis' website for historical purposes only. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.

Media Contacts

Media Contacts ›

Members of the media are welcome to contact our communications professionals.

For Novartis worldwide press contacts, visit the Novartis AG Newsroom

Photo Library

In the photo library you'll find downloadable images of members of the US Novartis Pharmaceuticals Corporation Executive Committee.

To access the photo library for the Global Novartis Executive Committee, company logos, locations and more, visit the Novartis.com Photo Library.

WHO WE ARE

We are a world leader in healthcare, with core businesses in pharmaceuticals, consumer health, generics, eye care, and animal health.

PRODUCTS

We strive to provide a broad range of innovative therapies and practical solutions.

RESEARCH & DEVELOPMENT

Research & Development

We maintain the most promising pipeline in the industry to treat and help people around the world.

INVESTORS

Investors

Find general financial information, company news, annual reports and financial statements.